David E. I. Pyott

Last updated

David Edmund Ian Pyott
Born1953
London, U.K.
Alma mater University of Edinburgh
London Business School
University College London
OccupationBusinessman

David Edmund Ian Pyott CBE (born 1953) was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. [1] In 2014 he was one of the 25 highest-paid CEOs in the United States. [2]

Contents

Early life

Pyott was born in 1953 in London, England. His parents were from Scotland; and, as a child, he lived in India, where his father worked in the sugar industry. [3]

Pyott received a Master of Arts degree from the University of Edinburgh in 1975 and a diploma in international and European law from the Europa Institute at the University of Amsterdam. He received a Master of Business Administration from the London Business School and an MS from the University College London in 1980. [4]

Career

Pyott worked for Sandoz Nutrition at various jobs from 1980 until 1990. From 1990 to 1992, Pyott served as the general manager of Sandoz Nutrition in Barcelona, Spain. From 1992 until 1995, he was the president and chief executive officer of Sandoz Nutrition Corporation. In 1995 Pyott transferred from Sandoz and joined Novartis AG, upon the merger of Sandoz and Ciba Geigy where he was head of the Nutrition Division until December 1997. [4] On January 1, 1998, he joined Allergan, which at that time was a small eye care business. [4] As of 2014, Pyott was one of the longest tenured pharmaceutical CEOs. [5] Under his leadership Allergan grew from a small eye care business to an international pharmaceutical and medical device company that earns over $5 billion a year. [6]

In 1998, Pyott joined the board of Allergan and became chairman in 2001. He has been a member of the board of Avery Dennison since 1999. He served on the board of Edwards Lifesciences Corporation from 2000 to 2014 and was a board member of Pacific Life from 2005 until 2007. [4] Pyott was chairman of California Healthcare Institute in 2003 and again in July 2012. [7] Pyott currently serves as the president of the International Council of Ophthalmology Foundation, [8] member of the board of the Pan American Ophthalmological Foundation, [9] member of the advisory board of the Foundation of the American Academy of Ophthalmology, [10] Retina Global [11] and the American Glaucoma Society Foundation. [12] David also serves on the boards of BioMarin Pharmaceutical, [13] Alnylam Pharmaceuticals, [14] Royal Philips, [15] Avery Dennison [16] and as chairman of privately held Bioniz Therapeutics. [17] He is deputy chairman of the governing board of London Business School and a member of the board of trustees of Caltech. [18] [19]

Allergan acquisition

On April 21, 2014, Bill Ackman of Pershing Square Capital Management teamed up with pharmaceutical company, Valeant Pharmaceuticals International Inc, to make a run at acquiring Allergan. [20] Rejecting the unsolicited $46 billion offer, as CEO, Pyott defended his company. [21] He believed selling to Valeant would not create long-term value for Allergan's shareholders due to Valeant's historic reliance on cost-cutting. [21] Pyott is known to value aggressive research and development for Allergan, which he said had enabled Allergan to launch several new products and increase annual sales by an average of 11% since 2011. [21] The R&D and marketing spends address consumer needs while providing value for shareholders, as was seen with Botox. [21] The rejection by Allergan, however, did not prevent Valeant and Pershing from pursuing the Botox maker further. [22]

Originally offering $48.30 per share, Valeant increased the cash portion of its offer to $58.30 per share. [23] Pyott and Allergan, standing tall on their beliefs, rejected the offer citing yet again Valeant's unsustainable business model. [24] As expected, this heated up the war between Pyott, Ackman and Valeant. In order to ward off the hostile takeover attempt, Allergan was courting other offers from companies with more sustainable business models. [25] On November 17, 2014, Allergan announced that they had agreed to a deal with Actavis plc for $66 billion, making it one of the world's largest drug makers by sales. [25] Pyott's decision to move forward with Actavis was based on the company's impressive management structure and desire to keep more of Allergan's research and development operation intact. [25] After the acquisition was finalized, Pyott elected not to join the combined company's board, but stayed on as chairman of The Allergan Foundation for a year. [26]

In July 2015, Actavis plc announced that the company adopted Allergan plc (NYSE: AGN) as the company name following the approval by Actavis shareholders on June 5. [27] The combination of the two companies created one of the world's top 10 pharmaceutical companies by revenue and a leader in a new industry model. [27]

As of March 15, 2015, Valeant's stock crashed more than 50%. [28] A number of factors contributed to the collapse of Valeant, many of which validate Pyott's approach to business. [29] Since the acquisition attempt and the subsequent fallout, Pyott's sentiments regarding Valeant have been vindicated. [30] Some have even gone as far to call Pyott a “hero” for saving Allergan and its shareholders and fighting for what he believes in. [31] [32]

Honors and awards

Throughout his career, Pyott has collected a number of honors and awards for his philanthropic efforts and his leadership at Allergan.

Related Research Articles

<span class="mw-page-title-main">Warner Chilcott</span> American pharmaceutical company

Warner Chilcott was a company in the pharmaceutical industry based in Rockaway, New Jersey. It was primarily focused on women's healthcare and dermatology. On October 1, 2013, the company was acquired by Actavis.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.

Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

<span class="mw-page-title-main">Bill Ackman</span> American billionaire hedge fund manager

William Albert Ackman is an American billionaire hedge fund manager who is the founder and chief executive officer of Pershing Square Capital Management, a hedge fund management company. His investment approach has made him an activist investor. As of January 2024, Ackman's net worth was estimated at $4 billion by Forbes.

<span class="mw-page-title-main">Tax inversion</span> Corporate relocation to a lower tax location

A tax inversion or corporate tax inversion is a form of tax avoidance where a corporation restructures so that the current parent is replaced by a foreign parent, and the original parent company becomes a subsidiary of the foreign parent, thus moving its tax residence to the foreign country. Executives and operational headquarters can stay in the original country. The US definition requires that the original shareholders remain a majority control of the post-inverted company. In US federal legislation a company which has been restructured in this manner is referred to as an "inverted domestic corporation", and the term "corporate expatriate" is also used.

<span class="mw-page-title-main">J. Michael Pearson</span>

J. Michael Pearson is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.

<span class="mw-page-title-main">Pershing Square Capital Management</span> American hedge fund

Pershing Square Capital Management is an American hedge fund management company founded and run by Bill Ackman, headquartered in New York City.

Andrew Edward Left is an activist, short seller, author and editor of the online investment newsletter Citron Research, formerly StockLemon.com. Under the name Citron Research, Left publishes reports on firms that he claims are overvalued or are engaged in fraud. Left is known for advising investors on short selling and has often appeared on various media outlets such as CNBC and Bloomberg to talk about his opinions on stocks. In 2017, Left was called 'The Bounty Hunter of Wall Street' by The New York Times. Left gained further notoriety following his announced short of GameStop, precipitating a short squeeze that has hurt him and other short sellers in the short term.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Greenhill & Co.</span> American investment bank

Greenhill & Co., Inc. is an American investment bank founded in 1996 by Robert F. Greenhill. The firm provides advice on mergers, acquisitions, restructurings, financings, and capital raisings to leading corporations, partnerships, institutions and governments across a number of industries.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, TN.

<span class="mw-page-title-main">Cindy Eckert</span> American entrepreneur

Cindy Eckert is an American entrepreneur known for founding Sprout Pharmaceuticals. She subsequently founded The Pink Ceiling which invests in companies founded by, or delivering products for, women. In November 2017, Eckert re-acquired Sprout Pharmaceuticals as part of a lawsuit settlement, and the rights to its drug Addyi, from Valeant after Valeant's stock collapsed due to insider trading and price jacking allegations.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He is helped lead various mergers and acquisitions and overseen the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

References

  1. ↑ Caleb Melby and Cynthia Koons for Bloomberg News. March 31, 2015 Ex-Allergan CEO Pyott Trades Stock for $534 Million Cash in Sale
  2. ↑ "America's 25 Highest Paid CEOs". Forbes. Retrieved 29 October 2014.
  3. ↑ Nash, Emily (3 October 2000). "Allergan's David Pyott His Coaching And Sharpened Focus Helped Revive Drugmaker". Investor's Business Daily. Archived from the original on 29 October 2014. Retrieved 29 October 2014.
  4. 1 2 3 4 "David E. I. Pyott". Bloomberg. Retrieved 8 June 2015.[ dead link ]
  5. ↑ Hirsch, Abigail (14 February 2014). "Fireside Chat with Allergan CEO, David Pyott". BIOtechNOW. Retrieved 29 October 2014. Day two of the 16th Annual BIO CEO & Investor Conference kicked off with a Fireside Chat featuring one of the longest tenured pharma CEOs, David E.I. Pyott, Chairman of the Board & Chief Executive Officer, Allergan.
  6. ↑ "A Conversation with Allergan CEO David Pyott". California Healthcare Institute. Retrieved 29 October 2014.
  7. ↑ Yu, Jane (19 July 2012). "Pyott Named Next Chair of California Healthcare". Orange County Business Journal. Retrieved 29 October 2014.
  8. ↑ "International Council of Ophthalmology : About the ICO : ICO Board and Advisory Committee". www.icoph.org. Archived from the original on 8 June 2019. Retrieved 16 September 2016.
  9. ↑ "PAAO – Pan-American Association of Ophthalmology". www.paao.org. Retrieved 16 September 2016.
  10. ↑ "Overview – American Academy of Ophthalmology". www.aao.org. Retrieved 16 September 2016.
  11. ↑ "Board – Retina Global" . Retrieved 16 September 2016.
  12. ↑ "David E. I. Pyott, CBE" (PDF). Archived from the original (PDF) on 20 September 2016. Retrieved 16 September 2016.
  13. ↑ "Board of Directors : BioMarin". www.biomarin.com. Retrieved 16 September 2016.
  14. ↑ "Board of Directors – Alnylam". www.alnylam.com. Archived from the original on 24 September 2016. Retrieved 16 September 2016.
  15. ↑ "Supervisory Board – Our management – Company – About | Philips" . Retrieved 16 September 2016.
  16. ↑ "Board of Directors | Avery Dennison". www.investors.averydennison.com. Archived from the original on 14 June 2017. Retrieved 16 September 2016.
  17. ↑ "Board of Directors – Bioniz Therapeutics". bioniz.com. Retrieved 16 September 2016.
  18. ↑ "Governance | London Business School" . Retrieved 16 September 2016.
  19. ↑ "David Pyott Elected as New Caltech Trustee" . Retrieved 29 January 2016.
  20. ↑ "Ackman, Valeant team up to bid for Allergan". Reuters. 22 April 2014. Retrieved 16 September 2016.
  21. 1 2 3 4 Walker, Joseph (13 May 2014). "Allergan Formally Rejects Valeant's $46 Billion Takeover Bid". Wall Street Journal. ISSN   0099-9660 . Retrieved 16 September 2016.
  22. ↑ Gelles, David. "In Rejecting Merger Bid, Allergan Focuses on Strategy" . Retrieved 16 September 2016.
  23. ↑ "Valeant Just Cranked Up Its Offer For Botox-Maker Allergan" . Retrieved 16 September 2016.
  24. ↑ Benoit, David (10 June 2014). "Allergan Rejects Valeant's Latest Takeover Bid". Wall Street Journal. ISSN   0099-9660 . Retrieved 16 September 2016.
  25. 1 2 3 Rockoff, Jonathan D. (18 November 2014). "Actavis Agrees to Buy Botox Maker Allergan". Wall Street Journal. ISSN   0099-9660 . Retrieved 16 September 2016.
  26. ↑ "Old Allergan CEO Pyott won't join New Allergan's board | FiercePharma". www.fiercepharma.com. Retrieved 16 September 2016.
  27. 1 2 "Actavis plc is now Allergan plc". Allergan. Retrieved 16 September 2016.
  28. ↑ Herper, Matthew. "Five Lessons Big Pharma Should Learn From Valeant's Collapse" . Retrieved 16 September 2016.
  29. ↑ Herper, Matthew. "Allergan's Attacks On Valeant Are Looking Eerily Prescient" . Retrieved 16 September 2016.
  30. ↑ Gapper, John (23 March 2016). "McKinsey's fingerprints are all over Valeant". Financial Times. ISSN   0307-1766 . Retrieved 16 September 2016.
  31. ↑ Investor, Uncommon Profit (9 November 2015). "Valeant – Why Bill Ackman Is Scared" . Retrieved 16 September 2016.
  32. ↑ Rockoff, Jonathan D.; Farrell, Maureen (22 October 2015). "Valeant Slumps Again After Rebutting Critical Report". Wall Street Journal. ISSN   0099-9660 . Retrieved 16 September 2016.
  33. ↑ "Hall of Fame | FCD – Forum for Corporate Directors, Orange County CA". fcdoc.org. Retrieved 16 September 2016.
  34. 1 2 3 "David Pyott Donor Spotlight – American Academy of Ophthalmology". www.aao.org. Retrieved 16 September 2016.
  35. ↑ "UCI News – 2010 Medal" . Retrieved 16 September 2016.
  36. ↑ "David Pyott | UCLA Anderson School of Management". www.anderson.ucla.edu. Retrieved 16 September 2016.
  37. ↑ "The Best-Performing CEOs in the World" . Retrieved 16 September 2016.
  38. ↑ "United Cerebral Palsy Gala Nets $518K - Newport Local News". 22 May 2015. Retrieved 16 September 2016.
  39. ↑ WINSLOW, JONATHAN. "Chapman's 'American Celebration' brings back some of its best moments for the show's 34th edition" . Retrieved 16 September 2016.
  40. ↑ "Honorary Graduates in 2016 | The University of Edinburgh". www.ed.ac.uk. Retrieved 16 September 2016.
  41. ↑ "David Pyott Elected as New Caltech Trustee" . Retrieved 21 January 2016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.